Literature DB >> 17635609

Activation of human CD4+ T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences.

Kayvan R Niazi1, Maria-Teresa Ochoa, Peter A Sieling, Nanette E Rooke, Anna K Peter, Pamela Mollahan, Micah Dickey, Shahrooz Rabizadeh, Thomas H Rea, Robert L Modlin.   

Abstract

Distinct CD4(+) T-cell epitopes within the same protein can be optimally processed and loaded into major histocompatibility complex (MHC) class II molecules in disparate endosomal compartments. The CD1 protein isoforms traffic to these same endosomal compartments as directed by unique cytoplasmic tail sequences, therefore we reasoned that antigen/CD1 chimeras containing the different CD1 cytoplasmic tail sequences could optimally target antigens to the MHC class II antigen presentation pathway. Evaluation of trafficking patterns revealed that all four human CD1-derived targeting sequences delivered antigen to the MHC class II antigen presentation pathway, to early/recycling, early/sorting and late endosomes/lysosomes. There was a preferential requirement for different CD1 targeting sequences for the optimal presentation of an MHC class II epitope in the following hierarchy: CD1b > CD1d = CD1c > > > CD1a or untargeted antigen. Therefore, the substitution of the CD1 ectodomain with heterologous proteins results in their traffic to distinct intracellular locations that intersect with MHC class II and this differential distribution leads to specific functional outcomes with respect to MHC class II antigen presentation. These findings may have implications in designing DNA vaccines, providing a greater variety of tools to generate T-cell responses against microbial pathogens or tumours.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635609      PMCID: PMC2266034          DOI: 10.1111/j.1365-2567.2007.02666.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

1.  Recognition of a lipid antigen by CD1-restricted alpha beta+ T cells.

Authors:  E M Beckman; S A Porcelli; C T Morita; S M Behar; S T Furlong; M B Brenner
Journal:  Nature       Date:  1994-12-15       Impact factor: 49.962

2.  Isolation and characterization of the intracellular MHC class II compartment.

Authors:  A Tulp; D Verwoerd; B Dobberstein; H L Ploegh; J Pieters
Journal:  Nature       Date:  1994-05-12       Impact factor: 49.962

3.  Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes.

Authors:  S Amigorena; J R Drake; P Webster; I Mellman
Journal:  Nature       Date:  1994-05-12       Impact factor: 49.962

4.  Cytoplasmic tail-dependent localization of CD1b antigen-presenting molecules to MIICs.

Authors:  M Sugita; R M Jackman; E van Donselaar; S M Behar; R A Rogers; P J Peters; M B Brenner; S A Porcelli
Journal:  Science       Date:  1996-07-19       Impact factor: 47.728

5.  CD1-restricted T cell recognition of microbial lipoglycan antigens.

Authors:  P A Sieling; D Chatterjee; S A Porcelli; T I Prigozy; R J Mazzaccaro; T Soriano; B R Bloom; M B Brenner; M Kronenberg; P J Brennan
Journal:  Science       Date:  1995-07-14       Impact factor: 47.728

6.  Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.

Authors:  T C Wu; F G Guarnieri; K F Staveley-O'Carroll; R P Viscidi; H I Levitsky; L Hedrick; K R Cho; J T August; D M Pardoll
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

7.  A regulatory role for ARF6 in receptor-mediated endocytosis.

Authors:  C D'Souza-Schorey; G Li; M I Colombo; P D Stahl
Journal:  Science       Date:  1995-02-24       Impact factor: 47.728

8.  Overexpression of wild-type and mutant ARF1 and ARF6: distinct perturbations of nonoverlapping membrane compartments.

Authors:  P J Peters; V W Hsu; C E Ooi; D Finazzi; S B Teal; V Oorschot; J G Donaldson; R D Klausner
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

9.  A pathway of costimulation that prevents anergy in CD28- T cells: B7-independent costimulation of CD1-restricted T cells.

Authors:  S M Behar; S A Porcelli; E M Beckman; M B Brenner
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

10.  Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes.

Authors:  C H Chang; J D Fontes; M Peterlin; R A Flavell
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

View more
  7 in total

1.  Interleukin-1β triggers the differentiation of macrophages with enhanced capacity to present mycobacterial antigen to T cells.

Authors:  Mirjam Schenk; Mario Fabri; Stephan R Krutzik; Delphine J Lee; David M Vu; Peter A Sieling; Dennis Montoya; Philip T Liu; Robert L Modlin
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

2.  Conserved mycobacterial lipoglycoproteins activate TLR2 but also require glycosylation for MHC class II-restricted T cell activation.

Authors:  Peter A Sieling; Preston J Hill; Karen M Dobos; Kerry Brookman; Andrew M Kuhlman; Mario Fabri; Stephan R Krutzik; Thomas H Rea; Darragh G Heaslip; John T Belisle; Robert L Modlin
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

3.  NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy.

Authors:  Mirjam Schenk; Stephan R Krutzik; Peter A Sieling; Delphine J Lee; Rosane M B Teles; Maria Teresa Ochoa; Evangelia Komisopoulou; Euzenir N Sarno; Thomas H Rea; Thomas G Graeber; Soohyun Kim; Genhong Cheng; Robert L Modlin
Journal:  Nat Med       Date:  2012-03-25       Impact factor: 53.440

Review 4.  The future of human DNA vaccines.

Authors:  Lei Li; Fadi Saade; Nikolai Petrovsky
Journal:  J Biotechnol       Date:  2012-09-07       Impact factor: 3.307

5.  Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein.

Authors:  Eleonora Zucchelli; Monika Pema; Anna Stornaiuolo; Claudia Piovan; Cinzia Scavullo; Erica Giuliani; Sergio Bossi; Stefano Corna; Claudia Asperti; Claudio Bordignon; Gian-Paolo Rizzardi; Chiara Bovolenta
Journal:  Mol Ther Methods Clin Dev       Date:  2017-01-11       Impact factor: 6.698

6.  Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies.

Authors:  Adrian Rice; Mohit Verma; Emily Voigt; Peter Battisti; Sam Beaver; Sierra Reed; Kyle Dinkins; Shivani Mody; Lise Zakin; Shiho Tanaka; Brett Morimoto; C Anders Olson; Elizabeth Gabitzsch; Jeffrey T Safrit; Patricia Spilman; Corey Casper; Patrick Soon-Shiong
Journal:  Front Immunol       Date:  2022-07-15       Impact factor: 8.786

Review 7.  Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic.

Authors:  Dimitrina Miteva; Monika Peshevska-Sekulovska; Violeta Snegarova; Hristiana Batselova; Radostina Alexandrova; Tsvetelina Velikova
Journal:  World J Virol       Date:  2022-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.